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Changes of Thyroidal Tc-99m Tetrofosmin
Uptake and Wash-Out in Patients with
Hashimoto’s Thyroiditis
ABS TRACT Objective: Our aim was to in ves ti ga te the chan ges in Tc-99m tet ro fos min up ta ke
and wash-out in the thyro id gland of nor mal vo lun te ers and Has hi mo to’s thyro i di tis (HT) pa ti -
ents with eit her euth yro i dism or hypoth yro i dism. Ma te ri al and Met hods: Thirty-fo ur pa ti ents
with HT (10 hypoth yro id and 24 euth yro id) and 10 euth yro id he althy vo lun te ers we re en rol led
in the study. In all ca ses, thyroid stimulating hormone (TSH), fre e thyro xi ne (FT4), fre e tri i o -
doth yro ni ne (FT3), an ti-thyro id an ti bo di es and thyro id vo lu me we re me a su red. An te ri or thyro -
id ima ges we re ac qu i red at 10, 30 and 120 min af ter in tra ve no us in jec ti on of 740 MBq Tc-99m
tet ro fos min. Thyro id/ back gro und (T/B) ra ti os at 10, 30 and 120 min and wash-out in di ces (WI
%) at 30 and 120 min we re cal cu la ted. Re sults: In all gro ups, ini ti al and la te tet ro fos min T/B va l-
u es did not dif fer from he althy con trol ca ses. At 120 min, the me an WI% of pa ti ents with hypoth -
yro i dism was sig ni fi cantly hig her than that of vo lun te ers; ho we ver this gro up is not sta tis ti cally
dif fe rent from the euth yro id gro up. The va lu e WI % at 120 min was sig ni fi cantly cor re la ted with
an ti-Tg an ti body le vels (r= -0.673; p= 0.033). In the euth yro id gro up, both an ti-TPO an ti body
le vels and thyro id vo lu me had sig ni fi cant cor re la ti ons with the T/B ra ti os at 10, 30 and 120 min
(r= 0.499, p= 0.013; r= 0.424, p= 0.039; r=0.528, p= 0.008 for An ti-TPO An ti body, and r= 0.577,
p= 0.003; r= 0.606, p= 0.002; r= 0.645, p= 0.010, for thyro id vo lu me, res pec ti vely). Conc lu si on: We
can conc lu de that Tc-99m tet ro fos min up ta ke and wash-out ki ne tics in thyro id tis su e may be
chan ged with au to im mu ne thyrocy te des truc ti on in HT. 
Key Words: Tech ne ti um Tc 99m tetrofosmin; Has hi mo to di se a se; ra di o nuc li de ima ging 
ÖZET Amaç: Ama cı mız öti ri o i dizm ve ya hi po ti ro i dizm li Has hi mo to Ti ro i dit li (HT) has ta la rın ve
sağ lık lı gö nül lü le rin ti ro id be zin de ki Tc-99m tet ro fos min tu tu lum ve atı lı mın da ki de ği şik lik le ri
araş tır mak tı. Ge reç ve Yön temler: Has hi mo to Ti ro i dit li 34 has ta (10’u hi po ti ro id ve 24’ü öti ro id) ve
10 öti ro id sağ lık lı gö nül lü ça lış ma ya alın dı. Tüm ol gu la rın tiroid stimule edici hormon (TSH), ser -
best ti rok sin (FT4), ser best tri i yo do ti ro nin (FT3), an ti-ti ro id an ti kor dü zey le ri ve ti ro id ha cim le ri
öl çül dü. İntra ve nöz ola rak 740 MBq Tc-99m tet ro fos min en jek si yo nun dan son ra 10, 30 ve 120 da -
ki ka lar da an te ri or ti ro id gö rün tü le ri alın dı. Bu gö rün tü ler den 10, 30, 120 dk ti ro id/ze min ak ti vi te
(T/B) oran la rı ve 30 ve 120 da ki ka da ki “wash-ou t” in deks le ri (%WI) he sap lan dı. Bul gu lar: Tüm
grup lar da, baş lan gıç ve geç tet ro fos min T/B de ğer le ri sağ lık lı kon trol ol gu la rın dan fark lı lık gös ter -
me di. Hi po ti ro i dizm li has ta la rın 120.dk’da ki or ta la ma %WI ’i gö nül lü ler den an lam lı şekil de da ha
yük sek ti, bu na kar şın öti ro id has ta lar dan an lam lı fark lı lık gös ter me di. Yüz yir min ci da ki ka %WI de -
ğe ri an ti-Tg an ti kor dü ze yi ile an lam lı ne ga tif ko re las yon için de idi (r= -0.673; p= 0.033). Öti ro id
grup ta, an ti-TPO an ti kor dü zey le ri ve ti ro id hac mi 10, 30 ve 120 dk T/B oran la rı ile an lam lı po zi -
tif ko re las yo na sa hip ti (An ti-TPO Ab için sı ra sı ile r= 0.499, p= 0.013; r= 0.424, p= 0.039; r= 0.528,
p= 0.008 ve ti ro id vo lü mü için sı ra sı ile r= 0.577, p= 0.003; r= 0.606, p= 0.002; r= 0.645, p= 0.010).
So nuç: Ti ro id be zin de ki Tc-99m tet ro fos min tu tu lu mu ve atı lı mı ki ne tik le ri nin HT de ki oto im mün
ti ro sit ha sa rı na ile de ği şe bi le ce ği so nu cu na va ra bi li riz. 
Anah tar Ke li me ler: Tc-99m tet ro fos min; Has hi mo to ti ro i di ti; sin tig ra fi  
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ORİJİNAL ARAŞTIRMA   
ashimoto’s thyroiditis (HT) (also known as
chro nic lymphocy tic thyro i di tis or chro -
nic au to im mu ne thyro i di tis) is a wi dely-
se en di se a se, par ti cu larly in yo ung wo men in
Ae ge an re gi on of Tur key. The co ur se of the di se a -
se va ri es and pa ti ents may ha ve nor mal thyroid
function or hypothyroidism at the time of initial
diagnosis.1-3
Tc-99m tetrofosmin (Tc-99m 1,2-bis[bis(2-
ethoxyethyl) phosphino]ethane) is a myocardial
perfusion imaging radiotracer such as Tc-99m
methoxyisobutylisonitrile (Tc-99m MI BI) or Tl-
201. Those thre e ra di op har ma ce u ti cals are al so
used as tu mor or pa rath yro id ima ging agents.4,5 The
in cre a sed up ta ke of Tc-99m MI BI or Tl-201 in the
thyro id gland has be en de mons tra ted in pa ti ents
with au to im mu ne thyro id di se a ses (Gra ves di se a se
and HT).6,7 Ho we ver, we ha ve hardly any informa-
tion regarding thyroid uptake of Tc-99m tetrofos-
min in patients with chronic autoimmune
thyroiditis; except only two published case reports.
In the first case with HT, Kresnik et al8 did not find
any increased Tc-99m tetrofosmin uptake or re-
tention in their patient, whereas Kao et al9 observed
an increased Tc-99m tetrofosmin uptake in their
patients.
In this study, we investigated the changes in
Tc-99m tetrofosmin uptake and wash-out in the
thyroid glands of normal volunteers and in patients
with euthyroid or hypothyroid HT. 
MATERIAL AND METHODS
Thirty-four patients with a previous diagnosis of
HT (4 M/ 30 F; mean age ± SD= 43 ± 13 years) and
10 euthyroid volunteers (3 M/ 7 F; mean age ± SD=
53 ± 14 years) were studied. Ages of patients with
HT were different from the ages of volunteers. This
prospective study was approved by the Faculty
Ethical Committee and informed consent was ob-
tained from all participants. 
The HT diagnosis was made on the basis of his-
tory and clinical examination, high anti-thyroid
antibody levels [Anti-thyroglobuline (Anti-Tg)> 40
IU/ml; Anti-thyroid peroxidase (Anti-TPO)> 35
IU/ml by electrochemical immunoassay (Immulite
2000, USA)], abnormal findings with thyroid ul-
trasonography (TUS) such as diffuse hypoechogen-
ity with pseudonodular changes and parenchymal
irregularity, and heterogeneous radiopharmaceuti-
cal uptake in Tc-99m pertechnetate thyroid scan-
ning. Cytological evaluation was not performed
during this study. 
Patients were grouped as hypothyroid (n= 10)
and euthyroid (n= 24), based on their thyroid stim-
ulating hormone (TSH) levels. Thyroid hormone
replacement therapy of patients with hypothy-
roidism was not stopped during study. 
The control group consisted of the cases with
no history of a new or previous diagnosis of goiter,
any kind of thyroiditis, abnormalities in thyroid
function tests or a systemic disorder. All volunteers
were chosen among people working in our hospi-
tal.
Cases with a history of thyroidectomy or
parathyroidectomy, those with palpable thyroid
nodules and/or TUS were excluded from the study
group. 
All patients and control cases underwent to
TUS and Tc-99m tetrofosmin thyroid scintigraphy. 
Thyroid volume was measured using a high-
resolution real-time ultrasound equipped by 7.5
MHz linear probe. Volumetric measurements
were obtained according to method of Ivanac et
al.10 Thyroid volumes were calculated according
to the spherical ellipsoid formula: volume = π/6 x
anteroposterior diameter (cm) x width (cm) x
length (cm). In each subject, measurements were
performed by the same physician.  The normal
thyroid volume determined by ultrasonography
was accepted as 11.1 ± 3.2 ml for females (upper
limit = 20.2 ml), 13.7 ± 3.4 ml for males (upper
limit= 22.4 ml) according to the report of Erdogan
et al.11 
All cases were subjected to Tc-99m tetrofos-
min scintigraphy. A CamStar AC/T gamma camera
(GE, Milwaukee, Wisc., USA) equipped by a LEAP
collimator was used for image acquisition. Planar
anterior neck images with a 256 × 256 matrix and
zoom of 1.33 were acquired at 10 min, 30 min and
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120 min for a 10 minute period following intra-
venous injection of Tc-99m tetrofosmin (My-
oviewÔ; Nycomed Amersham plc., Bucks, UK) at a
dose of 740 MBq (20 mCi).  
Regions of interest (ROIs) were drawn over
the whole thyroid gland and neck on each image.
The net count of the thyroid gland was calculated
by subtracting the neck counts from the thyroid
counts. Afterwards, thyroid/ background ratios on
the 10 min, 30 min and 120 min images, and wash-
out indices (WI %) for the 30 min and 120 min im-
ages were calculated using the formula given
below; 
WI %= [(early net thyroid cts-late net thyroid
cts) x 100/early net thyroid cts] 
Data were expressed as mean ± standard error.
A Kruskal-Wallis test was used to calculate the dif-
ference between the means of the three groups.
The significance of the means in Kruskal-Wallis
test was verified by the Mann-Whitney U test
with Bonferroni correction to protect against Type
I error due to multiple comparisons. Spearman’s
correlation analysis was used to evaluate the cor-
relation of Tc-99m tetrofosmin uptake and wash-
out kinetics with ultrasonographic thyroid volume
and serological tests (anti-thyroid antibodies) for
each group. The significance level was set at p≤
0.05. 
RESULTS
Early and late thyroid to background uptake (T/B)
ratios were very similar for each group (Table 1).
There was no significant difference between the ra-
tios of patients with each type of clinical status and
the healthy control cases (Figure 1). However, in
each group, the T/B ratios showed significant dif-
ferences from the 10 min to the 120 min time
points (p< 0.005).
The difference among the mean wash-out
rates of all the groups at 120 min was statistically
significant (p< 0.05). Tc-99m tetrofosmin WI % at
120 min. (71% ± 3%) in the hypothyroid group was
significantly higher than that of healthy volunteers
(57% ± 3%) (p< 0.05). Although the hypothyroid
group had rapid clearances at 30 min and 120 min
(29% ± 3% and 71% ± 3%, respectively) compared
to the euthyroid group (26% ± 1% and 64% ± 2%,
respectively), statistically significant differences
were not detected (Table 1, Figure 2) (p> 0.05). 
We performed correlation analysis for each
parameter. In the euthyroid group, the anti-TPO
antibody levels had significantly positive correla-
tions with the 10 min T/B ratios (r= 0.499; p=
0.013), 30 min T/B ratios (r= 0.424; p= 0.039) and
120 min T/B ratios (r= 0.528; p= 0.008). In the hy-
pothyroid group, no correlations were detected be-
tween anti-TPO antibody levels and T/B ratios. In
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Volunteers Euthyroidism Hypothyroidism p values*
N 10 24 10
Age (years) 53 ± 5 40 ± 2 47 ± 5 0.041***
Anti-Tg (< 40 IU/ml) < 20 154.25 ± 49.08 255.09 ± 66.03 0.034**
Anti-TPOAb (< 35 IU/ml) < 10 291.78 ± 78.11 940.53 ± 325.64 0.038**
Thyroid volume (mm3) 16.40 ± 2.1 15.57 ± 2.9 17.52 ± 11.52 0,761*
10 min T/B ratio 2.25 ± 0.17 2.40 ± 0.12 2.41 ± 0.27 0.976*
30 min T/B ratio 2.02 ± 0.17 2.12 ± 0.11 2.00 ± 0.16 0.914*
120 min T/B ratio 1.72 ± 0.12 1.67 ± 0.69 1.48 ± 0.09 0.248*
30 min WI % 26 ± 1 26 ± 1 29 ± 3 0.582*
120 min WI % 57 ± 3 64 ± 2 71 ± 3 0.042*
TABLE 1: Results of laboratory, ultrasonographic and scintigraphic parameters of the volunteers and the patients
(Values are presented as mean ± standard error).
*   Kruskal-Wallis Test.
**  Mann-Whitney U test was used for the comparisons between hypothyroid group and euthyroid group, could not be compared with volunteers. 
*** Mann-Whitney U test was used for the  comparisons between 34 Hashimoto’ thyroiditis patients and 10 volunteers.
both patient groups, we did not detect any correla-
tions between anti-Tg antibody levels and T/B ra-
tios at the three time points.
Thyroid volumes were normal (26 patients) or
hypertrophic (8 patients). In all patients with HT,
the thyroid volume had significant positive corre-
lations with T/B ratios (Table 2). The mean thyroid
volume in euthyroid group was observed as a bit
smaller than other two groups (Table 1). In this
group, the thyroid volume had significant positive
correlations with the 10 min T/B ratios (r= 0.577;
p= 0.003), 30 min T/B ratios (r= 0.606; p= 0.002) and
120 min T/B ratios (r= 0.645; p= 0.001). No corre-
lation was detected between the thyroid volume
and the T/B ratios in the hypothyroid group. We
did not find any relationship between thyroid vol-
ume and anti-thyroid antibody levels in both
groups (Table 2).
DISCUSSION
Only two cases in the literature have addressed the
thyroid Tc-99m tetrofosmin biokinetics in HT.8,9 It
has been reported that the kinetics of Tc-99m
Tetrofosmin in thyroid tissue and parathyroid le-
sions are different from Tc-99m methoxy isobutyl
isonitrile (MIBI) kinetics.12,13 In many studies, the
images were obtained at 30 and 120 min after in-
jection of radiopharmaceuticals in a dual phase Tc-
99m MIBI study, and, at 10 and 30 min
post-injection in a dual phase Tc-99m tetrofosmin
study.12-18 These acquisition time points are widely
used in parathyroid pathologies15,18-21 and thyroidi-
tis studies.9,22,23
In the present study, we evaluated the uptake
of thyroid Tc-99m tetrofosmin in patients with HT
and compared them with volunteers. We used
three imaging time points of 10 min, 30 min and
120 min. Tetrofosmin uptake ratios at all scanning
time points in HT groups were similar with con-
trols. Thyroid to background ratios calculated ac-
cording to these imaging times were almost same
with the results of Giordano et al,24 except for the
result of the 120 minute T/B of the hypothyroid
group (Table 1). In the hypothyroid group, the 120
minute T/B (1.48 ± 0.09) was markedly lower than
the result from Giordano’s study (1.65 ± 0.58). This
may be related to the healthy persons in their
study group which is different from our group
composing of hypothyroid patients. As mentioned
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FI GU RE 1: Thyro id to back gro und ra ti os of the thre e gro ups sho wed a dec -
re a se from 10 min to 120 min. Alt ho ugh the dec li ne of the hypoth yro id gro up
is mo re pro mi nent than the ot her two gro ups, the dif fe ren ces among the thre -
e gro ups are not sta tis ti cally sig ni fi cant.
FI GU RE 2: Com pa ri son of the wash-out in di ces of the thre e gro ups shows a
sig ni fi cant dif fe ren ce at 120 mi nu tes (p= 0.042 by Krus kal-Wal lis Test). The
hypoth yro id gro up ex hi bits a mo re ra pid cle a ran ce at 120 min than the vo lun-
te er gro up (p= 0.001 by Mann-Whit ney U test) (li ne with ar row he ads).
before, T/B ratios at 120 min. in the euthyroid
(1.67 ± 0.69) and the control (1.72 ± 0.12) groups
were the same as their results. Therefore, we sup-
posed that the number of functional thyroid cells
is one of the important factors effecting tetrofos-
min kinetics in the thyroid tissue. Because the
early tetrofosmin uptake into thyroid gland is the
reflection of blood pool activity, early tetrofosmin
uptake is not significantly different between the
hypothyroid patients and the volunteers. As the
late tetrofosmin uptake into thyroid gland shows
the number of functional thyroid cells, lower, up-
take compared to the volunteers may be associated
with degree of severity of the inflammatory or cy-
totoxic processes in the thyroid glands. The signif-
icant moderate correlation between thyroid
volume and T/B ratios in all the patients with HT
(Table 2) supports to this idea. Thus, late tetrofos-
min uptake decreases in hypothyroid group even
though thyroid volume measurements are not dif-
ferent from the others. Probably, inflammatory re-
action may affect result in reduced tetrofosmin
uptake in hypothyroid patients due to severe
oedema. 
We also detected changes in wash-out param-
eters in patients with hypothyroidism.99m Tc-tetro-
fosmin WI% at 120 minutes in the hypothyroid
group was significantly higher than that of healthy
volunteers (p= 0.011). A me an 71% of tet ro fos mi -
ne was was hed out from the thyro id gland un til the
120 mi nu te ti me po int. Alt ho ugh the hypoth yro id
gro up sho wed fas ter cle a ran ces at 30 min and 120
min com pa red with the euth yro id gro up, sta tis ti -
cally sig ni fi cant dif fe ren ces we re not de tec ted
(Tab le 1, Fi gu re 2).99m Tc-tet ro fos min 120 min
WI% va lu es of the pa ti ents with HT we re hig her
than tho se of vo lun te ers. Ho we ver, the dif fe ren ce
among the me an thyro id vo lu me of the gro ups was
not sta tis ti cally sig ni fi cant (p> 0.05). In this study,
thyroid hormone replacement therapy of patients
with hypothyroidism was not ceased during study.
Because of that, we assume that the basal metabo-
lism rates in patient groups were similar to those of
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T/B10min T/B 30 min T/B 120 min WI % 30 dk WI % 120 dk
All patients N 34 34 34 34 34
Anti-TPO r 0.261 0.235 0.195 -0.108 0.01
p 0.137 0.182 0.269 0,544 0.954
Anti-Tg r 0.120 0.056 0.380 0.043 0.023
p 0.499 0.753 0.832 0.809 0.896
US volume r 0.436 0.516 0.534 -0.329 -0.260
p 0.010 0.002 0.001 0.057 0.138
Euthyroid patients N 24 24 24 24 24
Anti-TPO r 0.499 0.424 0.528 -0.219 -0.076
p 0.013 0.039 0.008 0.304 0.723
Anti-Tg r 0.250 0.210 0.017 0.041 0.030
p 0.239 0.325 0.939 0.851 0.890
US volume r 0.577 0.606 0.645 -0.587 -0.374
p 0.003 0.002 0.010 0.003 0.072
Hypothyroid patients N 10 10 10 10 10
Anti-TPO r -0.224 -0.006 -0.176 -0.261 0.139
p 0.533 0.987 0.627 0.467 0.701
Anti-Tg r -0.273 0.067 0.345 -0.539 -0.673
p 0.446 0.855 0.328 0.108 0.033
US volume r -0.042 0.115 0.333 0.164 -0.261
p 0.907 0.751 0.347 0.651 0.467
TABLE 2: The correlative analysis of Tc-99m tetrofosmin T/B ratios and WI% values with anti-TPO antibody, 
anti-Tg antibody and US volume in patients with Hashimoto’s thyroiditis.
US: Ultrasonography, T/B: Thyroid/background.
the healthy cases, and the fibrosis of thyroid ef-
fecting the perfusion of thyrocytes did not develop
in hypothyroid patients. Thus, we suggest that the
changes in99m Tc-tetrofosmin kinetics in thyroid
tissue parallels the degree of thyrocyte destruction
in HT. Tetrofosmin is a perfusion agent,25 and is an
indicator of cell viability.26,27 Kresnik et al8 reported
decreased tetrofosmin uptake in patients with de-
generative goiter and HT in a late scan obtained at
1 h after injection. In other study, Younes et al25
showed that the mechanism of tetrofosmin uptake
was dependent on the amount of mitochondrial
proteins using cell-based systems. Based on the data
from Younes’s report,25 Kresnik et al8 suggested that
the decrease or loss of uptake capability in thyroid
tissue was due to degenerative changes.
This des truc ti ve pro cess that af fects thyro i dal
tet ro fos min ki ne tics de pends on au to im mu ne pat -
ho logy. We de tec ted that the an ti-Tg and an ti-TPO
an ti bo di es we re mar kedly high in the hypoth yro -
id gro up when com pa red to the euth yro id gro up
(p= 0.034 and p= 0.038, res pec ti vely). In the euth -
yro id gro up, the an ti-Tg an ti body le vels had sig ni -
fi cantly po si ti ve cor re la ti ons with 10 min, 30 min
and 120 min T/B ra ti os. Si mi larly, thyro id vo lu mes
al so had sig ni fi cantly po si ti ve cor re la ti ons with 10
min, 30 min and 120 min T/B ra ti os in euth yro id
pa ti ents. 
The se fin dings may be the in di rect evi den ce of
ac ti ve inf lam ma tory pro cess, be ca u se no correlation
was ob ser ved bet we en tet ro fos mi ne T/B ra ti os and
thyro id vo lu me in hypoth yro id pa ti ents. In the eu-
th yro id gro up, the po si ti ve cor re la ti ons of Tc-99m
tet ro fos min up ta ke with an ti-TPO an ti body le vels
and thyro id vo lu mes sug ges ted the ac ti ve inf lam -
ma tory pro cess. Our fin dings sup port the re sults of
Bog ner et al28 They re por ted that mic ro so mal an ti -
bo di es we re res pon sib le for the cyto to xic ef fect,
whe re as thyrog lo bu lin an ti bo di es did not me di a te
cyto to xi city. On the ot her hand, si mi lar to the re-
sults of Ri e u et al,29 we did not find any re la ti ons hip
bet we en thyro id vo lu me and an ti-TPO an ti body in
euth yro id or hypoth yro id pa ti ents. 
It has al re ady be en re por ted that au to im mu ne
re ac ti ons can aug ment fol li cu lar cell da ma ge.30 A
few stu di es re cently pub lis hed ha ve sho wn that the
high ex pres si on of key mo le cu les (such as fas, fas
li gand) that re gu la te cell de ath in HT pro mo te thy-
rocy te apop to sis, tis su e da ma ge and a gra du al re-
duc ti on in thyrocy te num bers, le a ding to
hypoth yro i dism.31-33 The re are few re ports abo ut
the use of Tc-99m tet ro fos min in di ag no sing apop-
to sis. Sü kan et al26 sho wed that sig ni fi cantly in cre -
a sed Tc-99m tet ro fos min up ta ke in to the bo ne
mar row was well cor re la ted with CD95, an in hi bi -
tor of apop to sis in pa ti ents with acu te le u ke mi a.
Wa ka su gi et al27 re por ted a ca se of ma lig nant phe -
oc hro mocy to ma that sho wed early in ten se up ta ke
and im me di a te ra pid wash-out of Tc-99m tet ro fos -
min. They al so cha rac te ri zed ove rex pres si on of the
an ti-apop to tic mo le cu le Bcl-2 in this ca se, which
was ref rac tory to I-131 MIBG the rapy.27 Sal ma so et
al34 re por ted that they did not ob ser ve any sig ni fi -
cant apop to sis in lymphocy tes in fil tra ting HT
glands, sug ges ting that the HT mic ro en vi ron ment
did not pro mo te lymphocy te apop to sis. The ex pres-
si on of the an ti-apop to tic mo le cu le Bcl-2 is in cre -
a sed in HT lymphocy tes and re du ced in thyrocy tes,
and the re gu la ti on of Fas/FasL/Bcl-2 ex pres si on in
HT can pro mo te thyrocy te apop to sis vi a ho mop hi -
lic Fa s- FasL in te rac ti ons, and a gra du al re duc ti on
in thyrocy te num bers le ads to hypoth yro i dism.35
Ba sed on the re sults of the se stu di es, we de du ce
that up-re gu la ti on of Fas and FasL and down-re gu -
la ti on of Bcl-2 pro te in ap pe ar to trig ger apop to sis in
thyro id fol li cu lar cells in HT. 
Although there are no reports about tetrofos-
min kinetics and apoptosis in HT, we can hypoth-
esise a possible connection between them based on
the results of the previous studies mentioned
above. The similarity in early T/B ratios for the
three groups (Table 1) suggests a reduction in blood
flow and membrane electrical gradient. The in-
creased thyroidal wash-out of tetrofosmin at 120
minutes in patients with HT is probably related to
thyrocyte apoptosis. Therefore, tetrofosmin scan-
ning appears to be a promising method to detect
apoptosis in thyroid tissue. Nevertheless, since we
did not perform fine-needle aspiration biopsy in
our patients, we could not estimate the extent of
apoptosis. Therefore, we cannot say that apoptosis
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is solely responsible for increased wash-out of
tetrofosmin, however it may change tetrofosmin
kinetics along with other cellular mechanisms,
such as blood flow rate, metabolic status and mem-
brane integrity in thyrocytes. 
As a conclusion, our findings show that the in-
creased 120 min wash-out index of99m Tc-tetrofos-
min, as a viability marker which may be related to
autoimmune cytotoxic processes. In addition, we
can say that the uptake and wash-out of99m Tc-
tetrofosmin in thyroid tissue in HT patients change
with the progression of disease. It needs further
studies to define the importance of regulating cell
death and the role of99m Tc-tetrofosmin in the de-
termination of apoptosis in autoimmune thyroid
disorders.
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